Last reviewed · How we verify
Temodal® or Dacarbazine Medac® — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Temodal® or Dacarbazine Medac® (Temodal® or Dacarbazine Medac®) — SentoClone AB.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Temodal® or Dacarbazine Medac® TARGET | Temodal® or Dacarbazine Medac® | SentoClone AB | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Temodal® or Dacarbazine Medac® CI watch — RSS
- Temodal® or Dacarbazine Medac® CI watch — Atom
- Temodal® or Dacarbazine Medac® CI watch — JSON
- Temodal® or Dacarbazine Medac® alone — RSS
Cite this brief
Drug Landscape (2026). Temodal® or Dacarbazine Medac® — Competitive Intelligence Brief. https://druglandscape.com/ci/temodal-or-dacarbazine-medac. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab